NASDAQ$BLTE
Belite Bio Inc · Q1 2025 earnings
Q1 2025 earnings · · Investor relations
Briefing
Belite Bio Q1 2025: net loss $14.3M, cash $157.4M funds PHOENIX trial
Belite Bio, Inc. reported first-quarter 2025 financial results for the period ended March 31, 2025. As a clinical-stage biopharmaceutical company, Belite reported no product revenue. The company posted a net loss of $14.3 million, compared with a net loss of $7.9 million in the prior-year quarter, reflecting higher research and development and general and administrative expenses. R&D expenses were $9.4 million, up from $6.8 million, driven by share-based compensation and higher PHOENIX trial costs. G&A expenses rose to $6.1 million from $1.6 million. As of March 31, 2025, Belite held $157.4 million in cash, liquidity funds, time deposits, and U.S. treasury bills following a $15 million registered direct offering in February 2025.
- Net loss of $14.3M vs $7.9M prior year; no product revenue as clinical-stage biotech
- R&D expenses $9.4M (+38%) on PHOENIX trial costs and share-based compensation
- G&A expenses $6.1M vs $1.6M prior year on increased share-based compensation
- Cash and liquid assets of $157.4M as of March 31, 2025 after $15M February offering
- Other income $1.2M from accrued interest on time deposits and U.S. treasury bills
Headline financials
Revenue & EPS history
Belite Bio · Revenue · Quarterly
$0
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 12 quarterly earnings reports · overlaid with Q1 2025
+0.3%
Avg return
Earnings day
+4.2%
Avg return
5 days after
+3.3%
Avg return
30 days after
31%
4 / 13 earnings
Positive
+36.6%
Q2 2022
Best reaction
-15.2%
Q4 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -6.5% | -1.0% | +5.5% | |
| Q1 2025 | -3.4% | +3.9% | +0.2% | |
| Q4 2024 | +0.5% | -0.2% | -15.1% | |
| Q3 2024 | +4.6% | +5.3% | -19.4% | |
| Q2 2024 | -1.4% | +1.3% | -2.1% | |
| Q1 2024 | -0.1% | +6.9% | +18.8% | |
| Q4 2023 | -15.2% | -16.5% | -13.6% | |
| Q3 2023 | -3.7% | -5.4% | +12.3% | |
| Q2 2023 | +2.3% | +4.2% | +39.9% | |
| Q4 2022 | -3.4% | -1.2% | -1.9% | |
| Q4 2020 | -3.4% | -1.2% | -1.9% | |
| Q4 2021 | -3.4% | -1.2% | -1.9% | |
| Q2 2022 | +36.6% | +59.4% | +21.7% | |
| Q3 2021 | — | — | — | |
| Q2 2021 | — | — | — | |
| Q1 2021 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro